Imetelstat Demonstrates Meaningful Quality of Life Improvements in Lower-Risk Myelodysplastic Syndromes
recent research presented at the European Hematology Association 2025 Congress highlights a notable positive impact of imetelstat (Rytelo; Geron) on the well-being of individuals battling lower-risk Myelodysplastic Syndromes (MDS). A detailed analysis of data from the IMerge trial reveals that patients receiving imetelstat experienced significant and sustained improvements in health-related quality of life, a critical factor often overlooked in traditional MDS treatment assessments.
Enhanced patient Well-being: Key Findings
The study focused on evaluating changes in the QOL in Myelodysplasia Scale (QUALMS), a validated tool used to measure the impact of MDS on a patient’s daily life. Researchers discovered a substantially higher percentage of patients in the imetelstat group demonstrated improvements in both total and physical burden scores compared to those receiving a placebo.Specifically, the analysis showed that imetelstat not only improved quality of life but also maintained it over time. Conversely, patients in the placebo group generally experienced a decline in their QUALMS scores. This difference was notably pronounced in the early stages of treatment,suggesting a rapid positive effect from imetelstat.
Linking Treatment Response to Quality of Life
A crucial aspect of the research was determining whether the observed improvements were simply due to the characteristics of patients who responded well to the drug, or a direct result of imetelstat itself. the findings strongly support the latter.
Researchers compared patients who responded to imetelstat with those who did not. Those exhibiting a positive response to the medication showed considerably greater improvements in total, physical, and emotional QUALMS scores. This correlation underscores that the benefits experienced are intrinsically linked to the drug’s efficacy.
Impact on Transfusion-Dependent Patients
The positive effects of imetelstat were especially notable in patients requiring regular blood transfusions – a common and burdensome aspect of MDS management. A larger proportion of transfusion-dependent patients treated with imetelstat reported sustained meaningful improvements in their QUALMS scores compared to non-responders. Considering that approximately 40% of MDS patients require regular transfusions, this finding is particularly significant.
These results emphasize that imetelstat offers a potential pathway to not only address the underlying disease but also to substantially enhance the quality of life for individuals living with lower-risk MDS, particularly those heavily reliant on transfusions. The data reinforces the importance of considering patient-reported outcomes in evaluating treatment success for this challenging condition.